Aptadel’s technology is based in a delivery platform for RNA therapeutic agents. Our Aptamers technology allows us to conjugate numerous therapeutic agents directed against tumour cells with improved safety and specificity.
Aptadel's pipeline status
Aptadel’s main program is dedicated to fight childhood cancer, in particular Ewing Sarcoma (ES). ES is a rare type of cancerous tumour that grows in bones or soft tissue. It mainly affects children and young people, but is also seen in adults. These tumors are very aggressive, they tend to reappear and develop metastasis after chemotherapy. ES is the second most diagnosed form of primary bone cancer in children and young adults. Due to the lack of effective treatments, the survival of patients with pediatric sarcoma that present metastasis at the time of diagnosis is barely 20%.
Aptadel’s platform allows the targeting of a wide variety of cancer types. ADEL-101 and ADEL-102 are targeting paediatric cancers and ADEL-103 is targeting adult cancers